Figure 1
Figure 1. HLA class I and II surface expression on myeloma patient and HV bone marrow cells. Quantification of HLA surface expression was performed using a bead-based flow cytometric assay. (A) HLA class I and (B) HLA-DR expression on CD38+CD138+ primary myeloma cells compared with autologous CD34+CD38− HPCs, CD19+CD20+ B cells, and CD3+ T cells. (C) HLA class I and (D) HLA-DR expression on primary MM cells compared with bone marrow–derived plasma cells of HVs. n.s., not significant; *P < .05; **P < .01; ***P < .001.

HLA class I and II surface expression on myeloma patient and HV bone marrow cells. Quantification of HLA surface expression was performed using a bead-based flow cytometric assay. (A) HLA class I and (B) HLA-DR expression on CD38+CD138+ primary myeloma cells compared with autologous CD34+CD38 HPCs, CD19+CD20+ B cells, and CD3+ T cells. (C) HLA class I and (D) HLA-DR expression on primary MM cells compared with bone marrow–derived plasma cells of HVs. n.s., not significant; *P < .05; **P < .01; ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal